<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01792804</url>
  </required_header>
  <id_info>
    <org_study_id>Uni-Koeln-1400</org_study_id>
    <secondary_id>2013-000577-77</secondary_id>
    <nct_id>NCT01792804</nct_id>
  </id_info>
  <brief_title>Staphylococcus Aureus Bacteremia Antibiotic Treatment Options</brief_title>
  <acronym>SABATO</acronym>
  <official_title>Early Oral Switch Therapy in Low-risk Staphylococcus Aureus Bloodstream Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing resistance to antibiotic agents has been recognized as a major health problem&#xD;
      worldwide that will even aggravate due to the lack of new antimicrobial agents within the&#xD;
      next decade [1]. This threat underscores the need to maximize clinical utility of existing&#xD;
      antibiotics, through more rational prescription, e.g. optimizing duration of treatment.&#xD;
&#xD;
      Staphylococcus aureus bloodstream infection (SAB) is a common disease with about 200,000&#xD;
      cases occurring annually in Europe [2]. A course of at least 14 days of intravenous&#xD;
      antimicrobials is considered standard therapy [3-5] in &quot;uncomplicated&quot; SAB. This relatively&#xD;
      long course serves to prevent SAB-related complications (such as endocarditis and vertebral&#xD;
      osteomyelitis) that may result from hematogenous dissemination to distant sites. However,&#xD;
      there is insufficient evidence that a full course of intravenous antibiotic therapy is always&#xD;
      required in patients with a low risk of SAB-related complications.&#xD;
&#xD;
      In a multicenter, open-label, randomized controlled trial we aim to demonstrate that an early&#xD;
      switch from intravenous to oral antimicrobial therapy is non-inferior to a conventional&#xD;
      14-days course of intravenous therapy regarding efficacy and safety. An early switch from&#xD;
      intravenous to oral therapy would provide several benefits such as earlier discharge, fewer&#xD;
      adverse reactions associated with intravenous therapy, increased quality of life, and cost&#xD;
      savings.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. WHO. WHO Global Strategy for Containment of Antimicrobial Resistance.: World Health&#xD;
           Organization, 2001.&#xD;
&#xD;
        2. Kern WV. Management of Staphylococcus aureus bacteremia and endocarditis: progresses and&#xD;
           challenges. Curr Opin Infect Dis 2010;23(4):346-58.&#xD;
&#xD;
        3. Gemmell CG, Edwards DI, Fraise AP, Gould FK, Ridgway GL, Warren RE. Guidelines for the&#xD;
           prophylaxis and treatment of methicillin-resistant Staphylococcus aureus (MRSA)&#xD;
           infections in the UK. J Antimicrob Chemother 2006;57(4):589-608.&#xD;
&#xD;
        4. Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious&#xD;
           Diseases Society of America for the treatment of methicillin-resistant Staphylococcus&#xD;
           aureus infections in adults and children. Clin Infect Dis 2011;52(3):e18-55.&#xD;
&#xD;
        5. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and&#xD;
           management of intravascular catheter-related infection: 2009 Update by the Infectious&#xD;
           Diseases Society of America. Clin Infect Dis 2009;49(1):1-45.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2013</start_date>
  <completion_date type="Actual">March 26, 2020</completion_date>
  <primary_completion_date type="Actual">March 26, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>SAB-related complications</measure>
    <time_frame>90 days</time_frame>
    <description>S. aureus bloodstream infection-related complications (relapsing SAB, deep-seated infection with S. aureus, or attributable mortality) within 90 days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>90 days</time_frame>
    <description>Length of hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>14, 30, and 90 days</time_frame>
    <description>Survival at 14, 30, and 90 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications of intravenous therapy</measure>
    <time_frame>90 days</time_frame>
    <description>Complications of intravenous therapy, such as thrombophlebitis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clostridium difficile associated diarrhea (CDAD)</measure>
    <time_frame>90 days</time_frame>
    <description>Clostridium difficile associated diarrhea (CDAD)</description>
  </other_outcome>
  <other_outcome>
    <measure>AEs and SAEs</measure>
    <time_frame>90 days</time_frame>
    <description>Adverse events</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">215</enrollment>
  <condition>Staphylococcus Aureus Infection</condition>
  <arm_group>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First choice (MRSA and MSSA): trimethoprim-sulfamethoxazole, or Second choice (MSSA): clindamycin, or Second choice (MRSA): linezolid administered for 7-9 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First choice (MSSA): flucloxacillin [Spain: cloxacillin], or cefazolin or Second choice (MSSA): vancomycin, or First choice (MRSA): vancomycin, or Second choice (MRSA): daptomycin administered for 7-9 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trimethoprim-Sulfamethoxazole</intervention_name>
    <description>study drug 1</description>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin</intervention_name>
    <description>study drug 2</description>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>study drug 3</description>
    <arm_group_label>Orally administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flucloxacillin</intervention_name>
    <description>study drug 4</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cloxacillin</intervention_name>
    <description>study drug 5</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>study drug 6</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Daptomycin</intervention_name>
    <description>study drug 7</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cefazolin</intervention_name>
    <description>study drug 8</description>
    <arm_group_label>Intravenously administered antibiotic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age at least 18 years&#xD;
&#xD;
          -  Not legally incapacitated&#xD;
&#xD;
          -  Written informed consent from the trial subject has been obtained&#xD;
&#xD;
          -  Blood culture positive for S. aureus not considered to represent contamination&#xD;
&#xD;
          -  At least one negative follow-up blood culture obtained within 24-96 hours after the&#xD;
             start of adequate antimicrobial therapy to rule out persistent bacteremia and Absence&#xD;
             of a blood culture positive for S. aureus at the same time or thereafter.&#xD;
&#xD;
          -  Five to seven full days of appropriate i.v. antimicrobial therapy administered prior&#xD;
             to randomization documented in the patient Chart. Appropriate therapy has all of the&#xD;
             following characteristics:&#xD;
&#xD;
               1. Antimicrobial therapy has to be initiated within 72h after the first positive&#xD;
                  blood culture was drawn.&#xD;
&#xD;
               2. Provided in-vitro susceptibility and adequate dosing (as judged by the PI)&#xD;
                  preferred agents for pre-randomization antimicrobial therapy are flucloxacillin,&#xD;
                  cloxacillin, vancomycin and daptomycin. However, the following antimicrobials are&#xD;
                  allowed:&#xD;
&#xD;
                    -  MSSR: penicillinase-resistant penicillins (e.g. flucloxacillin,&#xD;
                       cloxacillin), β-lactam plus β-lactamase-inhibitors (e.g.&#xD;
                       ampicillin+sulbactam, piperacillin+tazobactam), cephalosporins (except&#xD;
                       ceftazidime), carbapenems, clindamycin, fluoroquinolones,&#xD;
                       trimethoprimsulfamethoxazole, doxycycline, tigecycline, vancomycin,&#xD;
                       teicoplanin, telavancin, linezolid, daptomycin, ceftaroline, ceftobiprole,&#xD;
                       and macrolides.&#xD;
&#xD;
                    -  MRSA: vancomycin, teicoplanin, telavancin, fluoroquinolones, clindamycin,&#xD;
                       trimethoprim-sulfamethoxazole, doxycycline, tigecycline, linezolid,&#xD;
                       daptomycin, macrolides, ceftaroline, and ceftobiprole.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Polymicrobial bloodstream infection, defined as isolation of pathogens other than S.&#xD;
             aureus from a blood culture obtained in the time from two days prior to the first&#xD;
             positive blood culture with S. aureus until randomization. Common skin contaminants&#xD;
             (coagulase-negative staphylococci, diphtheroids, Bacillus spp., and Propionibacterium&#xD;
             spp.) detected in one of several blood cultures will not be considered to represent&#xD;
             polymicrobial infection&#xD;
&#xD;
          -  Recent history (within 3 months) of prior S. aureus bloodstream infection&#xD;
&#xD;
          -  In vitro resistance of S. aureus to all oral or all i.v. study drugs&#xD;
&#xD;
          -  Contraindications for all oral or all i.v. study drugs&#xD;
&#xD;
          -  Previously planned Treatment with active drug against S. aureus during Intervention&#xD;
             Phase (e.g. cotrimoxazol prophylaxis)&#xD;
&#xD;
          -  Signs and symptoms of complicated SAB as judged by an ID physician. Complicated&#xD;
             infection is defined as at least one of the following:&#xD;
&#xD;
               -  deep-seated focus: e.g. endocarditis, pneumonia, undrained abscess, empyema, and&#xD;
                  Osteomyelitis&#xD;
&#xD;
               -  septic shock, as defined by the AACP criteria (23), within 4 days before&#xD;
                  randomization&#xD;
&#xD;
               -  prolonged bacteremia: positive follow-up blood culture more than 72h after the&#xD;
                  start of adequate antimicrobial therapy&#xD;
&#xD;
               -  body temperature &gt;38 °C on two separate days within 48h before randomization&#xD;
&#xD;
          -  Presence of the following non-removable foreign bodies (if not removed 2 days or more&#xD;
             before randomization):&#xD;
&#xD;
               -  prosthetic heart valve&#xD;
&#xD;
               -  deep-seated vascular graft with foreign material (e.g. PTFE or dacron graft).&#xD;
                  Hemodialysis shunts are not considered deep-seated vascular grafts.&#xD;
&#xD;
               -  ventriculo-atrial shunt&#xD;
&#xD;
          -  Presence of a prosthetic joint (if not removed 2 days or more before randomization).&#xD;
             This is not an exclusion criterion, if all of the following conditions are fulfilled:&#xD;
&#xD;
               -  prosthetic joint was implanted at least 6 months prior, and&#xD;
&#xD;
               -  catheter-related infection, skin and soft tissue infection, or surgical wound&#xD;
                  infection is present (as defined below), and&#xD;
&#xD;
               -  joint infection unlikely (no clinical or imaging signs)&#xD;
&#xD;
          -  Presence of a pacemaker or an automated implantable cardioverter Defibrillator (AICD)&#xD;
             device (if not removed 2 days or more before randomization). This is not an exclusion&#xD;
             criterion, if all of the following conditions are fulfilled:&#xD;
&#xD;
               -  pacemaker or AICD was implanted at least 6 months prior, and&#xD;
&#xD;
               -  catheter-related infection, skin and soft tissue infection, or surgical wound&#xD;
                  infection is present (as defined below), and&#xD;
&#xD;
               -  no clinical signs of infective endocarditis, and&#xD;
&#xD;
               -  infective endocarditis unlikely by echocardiography (preferably TEE), and&#xD;
&#xD;
               -  pocket infection unlikely (no clinical or imaging signs)&#xD;
&#xD;
          -  Failure to remove any intravascular catheter which was present when first positive&#xD;
             blood culture was drawn within 4 days of the first positive blood culture&#xD;
&#xD;
          -  Severe liver disease. This is not an exclusion criterion, if the following condition&#xD;
             is fulfilled:&#xD;
&#xD;
             - catheter-related infection, skin and soft tissue infection, or surgical wound&#xD;
             infection is present&#xD;
&#xD;
          -  End-stage renal disease. This is not an exclusion criterion, if all of the following&#xD;
             conditions are fulfilled:&#xD;
&#xD;
               -  catheter-related infection, skin and soft tissue infection, or surgical wound&#xD;
                  infection is present (as defined below), and&#xD;
&#xD;
               -  no clinical signs of infective endocarditis, and&#xD;
&#xD;
               -  infective endocarditis unlikely by echocardiography (preferably TEE), and&#xD;
&#xD;
               -  in patients with a hemodialysis shunt with a non-removable foreign body (e.g.&#xD;
                  synthetic PTFE loop): no clinical signs of a shunt infection&#xD;
&#xD;
          -  Severe immunodeficiency&#xD;
&#xD;
               -  primary immunodeficiency disorders&#xD;
&#xD;
               -  neutropenia (&lt;500 neutrophils/μl) at randomization or neutropenia expected during&#xD;
                  intervention phase due to immunosuppressive treatment&#xD;
&#xD;
               -  uncontrolled disease in HIV-positive patients&#xD;
&#xD;
               -  high-dose steroid therapy (&gt;1 mg/kg prednisone or equivalent doses given for &gt;4&#xD;
                  weeks or planned during intervention)&#xD;
&#xD;
               -  immunosuppressive combination therapy with two or more drugs with different mode&#xD;
                  of action&#xD;
&#xD;
               -  hematopoietic stem cell transplantation within the past 6 months or planned&#xD;
                  during treatment period&#xD;
&#xD;
               -  solid organ transplant&#xD;
&#xD;
               -  treatment with biologicals within the previous year&#xD;
&#xD;
          -  Life expectancy &lt; 3 months&#xD;
&#xD;
          -  Inability to take oral drugs&#xD;
&#xD;
          -  Injection drug user&#xD;
&#xD;
          -  Expected low compliance with drug regimen&#xD;
&#xD;
          -  Participation in other interventional trials within the previous three months or&#xD;
             ongoing&#xD;
&#xD;
          -  Pregnant women and nursing mothers&#xD;
&#xD;
          -  For premenopausal women: Failure to use highly-effective contraceptive methods for 1&#xD;
             month after receiving study drug. The following contraceptive methods with a Pearl&#xD;
             Index lower than 1% are regarded as highly-effective:&#xD;
&#xD;
               -  oral hormonal contraception ('pill')&#xD;
&#xD;
               -  dermal hormonal contraception&#xD;
&#xD;
               -  vaginal hormonal contraception (NuvaRing®)&#xD;
&#xD;
               -  contraceptive plaster&#xD;
&#xD;
               -  long-acting injectable contraceptives&#xD;
&#xD;
               -  implants that release progesterone (Implanon®)&#xD;
&#xD;
               -  tubal ligation (female sterilisation)&#xD;
&#xD;
               -  intrauterine devices that release hormones (hormone spiral)&#xD;
&#xD;
               -  double barrier methods&#xD;
&#xD;
          -  Persons with any kind of dependency on the investigator or employed by the sponsor or&#xD;
             investigator&#xD;
&#xD;
          -  Persons held in an institution by legal or official order&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Achim J Kaasch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine University, Duesseldorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chambéry</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>La Roche-sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orléans</name>
      <address>
        <city>Orléans</city>
        <zip>45100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris 5</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris 1</name>
      <address>
        <city>Paris</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris 3</name>
      <address>
        <city>Paris</city>
        <zip>92110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris 2</name>
      <address>
        <city>Paris</city>
        <zip>93000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paris 4</name>
      <address>
        <city>Paris</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Quimper</name>
      <address>
        <city>Quimper</city>
        <zip>29107</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tours</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Cologne</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Düsseldorf</name>
      <address>
        <city>Dusseldorf</city>
        <zip>40225</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankfurt</name>
      <address>
        <city>Frankfurt/Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jena</name>
      <address>
        <city>Jena</city>
        <zip>07743</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krefeld</name>
      <address>
        <city>Krefeld</city>
        <zip>47805</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leverkusen</name>
      <address>
        <city>Leverkusen</city>
        <zip>51375</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23562</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VUmc Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1081</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amsterdam</name>
      <address>
        <city>Amsterdam</city>
        <zip>1105 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Breda</name>
      <address>
        <city>Breda</city>
        <zip>4814 CK Breda</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tilburg</name>
      <address>
        <city>Tilburg</city>
        <zip>5022GC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>5022</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barcelona II</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barcelona I</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palma</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sevilla II</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sevilla</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham</name>
      <address>
        <city>Nottingham</city>
        <zip>NG7 24 H</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 13, 2013</study_first_submitted>
  <study_first_submitted_qc>February 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2013</study_first_posted>
  <last_update_submitted>May 26, 2020</last_update_submitted>
  <last_update_submitted_qc>May 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>Bloodstream infection</keyword>
  <keyword>Oral switch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Cefazolin</mesh_term>
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Daptomycin</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Floxacillin</mesh_term>
    <mesh_term>Cloxacillin</mesh_term>
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

